Form 4 for NVCR NovoCure Ltd
Accepted 2022-11-03 00:00:00 ET · period of report 2022-11-01 · accession 0001645113-22-000093 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-03 | 2022-11-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +6,830 | 50.5K | +16% | $0 |
| D | 2022-11-03 | 2022-11-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $73.20 | +11.6K | 11.6K | New | +$849.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-11-01 | A | A | 6,830 | $0.00 | 50,456 | D | — | — | (F1) Represents restricted share units that are scheduled to vest in equal installments on each of November 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. |
| 2 | Derivative | Options to Buy Ordinary Shares | 2022-11-01 | A | A | 11,609 | $73.20 | 11,609 | D | $73.20 · 2023-11-01 to 2032-10-31 | 11,609 Ordinary Shares | (F2) Options to buy 11,609 ordinary shares will vest and become exercisable in equal installments on each of November 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. |